Regeneron Pharms

REGN NASDAQ
295.49
-0.54
-0.18%
Opening 14:43 08/21 EDT
Open
297.98
Prev Close
296.03
High
300.51
Low
295.21
Volume
300.57K
Avg Vol (3M)
794.12K
52 Week High
442.00
52 Week Low
287.66
% Turnover
0.27%
Market Cap
32.45B
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Regeneron Pharms REGN stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.
MORE >

Recently

Name
Price
%Change